INTRODUCTION: The paper aims at evaluating the role of testosterone levels and their cut-off points in the treatment of prostate cancer with androgen deprivation therapy. MATERIALS AND METHODS: We performed a non-systematic review of the literature, searching Medline using the following key words: 'Prostatic neoplasms/therapy' [MeSH], 'Buserelin' [MeSH], 'Goserelin' [MeSH], 'Leuprolide' [MeSH], 'Triptorelin' [MeSH], 'prostate cancer*' [tiab], and 'testoster*' [tiab]. RESULTS: The most commonly used cut-off point of testosterone to define castration was 50 ng/dl. In this respect, GnRH agonists allowed castration in a very high percentage of patients (87.5-100%). Specifically, triptorelin was reported to yield castration level of testosterone in 98.8%, the classical formulation of leuprolide in 95-98.8% of the cases, and Eligard, a novel formulation of leuprolide, in 99-100%. With regard to the 20-ng/dl breakpoint, available data suggest that goserelin yields castration level of testosterone in 96%, the classical formulation of leuprolide in 87-92% of the patients, and the novel formulation in 88-97.5%. CONCLUSIONS: The clinical significance of different levels of testosterone yielded during androgen deprivation therapy is still unknown. Considering the standard cut-off point of 50 ng/dl, GnRH agonists allowed castration in a very high percentage of patients. Copyright 2009 S. Karger AG, Basel.
INTRODUCTION: The paper aims at evaluating the role of testosterone levels and their cut-off points in the treatment of prostate cancer with androgen deprivation therapy. MATERIALS AND METHODS: We performed a non-systematic review of the literature, searching Medline using the following key words: 'Prostatic neoplasms/therapy' [MeSH], 'Buserelin' [MeSH], 'Goserelin' [MeSH], 'Leuprolide' [MeSH], 'Triptorelin' [MeSH], 'prostate cancer*' [tiab], and 'testoster*' [tiab]. RESULTS: The most commonly used cut-off point of testosterone to define castration was 50 ng/dl. In this respect, GnRH agonists allowed castration in a very high percentage of patients (87.5-100%). Specifically, triptorelin was reported to yield castration level of testosterone in 98.8%, the classical formulation of leuprolide in 95-98.8% of the cases, and Eligard, a novel formulation of leuprolide, in 99-100%. With regard to the 20-ng/dl breakpoint, available data suggest that goserelin yields castration level of testosterone in 96%, the classical formulation of leuprolide in 87-92% of the patients, and the novel formulation in 88-97.5%. CONCLUSIONS: The clinical significance of different levels of testosterone yielded during androgen deprivation therapy is still unknown. Considering the standard cut-off point of 50 ng/dl, GnRH agonists allowed castration in a very high percentage of patients. Copyright 2009 S. Karger AG, Basel.
Authors: Élcio Dias Silva; Ubirajara Ferreira; Wagner Matheus; Eliney F Faria; Gustavo D Silva; Minori Saito; Auro A S de Souza; Azuil Laranjo; Otavio Clark; Luis Alberto Magna; Lísias Nogueira Castilho; Leonardo Oliveira Reis Journal: Int Urol Nephrol Date: 2012-08 Impact factor: 2.370
Authors: Kyle O Rove; E David Crawford; Massimo Perachino; Juan Morote; Laurence Klotz; Paul H Lange; Gerald L Andriole; Alvin M Matsumoto; Samir S Taneja; Mario A Eisenberger; Leonardo O Reis Journal: Urology Date: 2014-04-06 Impact factor: 2.649